The California Institute for Regenerative Medicine (CIRM) gave out $42 million in grants designed to recruit stem cell researchers to the state and back human clinical trials, including a Phase I trial for Sangamo BioSciences's beta-thalassemia therapy.
Richmond, California-based Sangamo won a four-year, $6.37 million grant under CIRM's Strategic Partnership program to evaluate the company's zinc finger nuclease (ZFN) gene-editing technology in hematopoietic stem cell (HSC) transplants...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?